VCBeat Health Contact Us
Home LTZ Therapeutics Enters Strategic Collaboration with GSK for $50 Million Upfront to Advance Myeloid Cell Engager Platform

LTZ Therapeutics Enters Strategic Collaboration with GSK for $50 Million Upfront to Advance Myeloid Cell Engager Platform

Nov 19, 2025 17:18 CST Updated 17:18
GSK

Pharmaceutical R&D Manufacturer

LTZ Therapeutics

Immunotherapy Developer

Image

Vacancy Available, Seeking Talented IndividualsImageImageImage

DrugTimes Recruitment【Senior BD Manager / BD Manager】

Interested young talents are invited to submit their resumes to

DrugTimes HR Department

HR@drugtimes.cn


Main Body:1300Word

Estimated reading time: 3 minutes

On November 19, 2025, GSK announced its collaboration with LTZ Therapeutics.Pharmaceuticals(LTZ Therapeutics) have reached a cooperation, and both parties willJointly advance the development of a new generation of myeloid cell engager (MCE) therapy.
Image
The Cooperation PlanDevelopmentUp to four first-in-class therapies targeting hematologic malignancies and solid tumors globally.According to the agreement,GSK will obtain exclusive priority to develop and commercialize these preclinical therapies globally.LTZ TherapeuticsWillReceived a prepayment of 50 million US dollars,And is eligible for subsequent milestone payments and a certain percentage of sales dividends.
It is worth mentioning that this cooperation in July this yearLTZ Therapeutics and Eli Lilly's cooperation targets are basically the same, both areMCE Platform. Recommended Reading:Setting Sail! LTZ Therapeutics & Eli Lilly Forge Partnership to Advance Autoimmune Pipeline Development
LTZ Therapeutics' MCE platform activates innate receptors on myeloid cells after binding to target-associated antigens (TAA) on target cells, thereby enabling phagocytosis and potent depletion of the targeted cells. The platform boasts four key highlights:
(1) In the presence of target cells, the platform activates myeloid cells to perform phagocytosis with minimal release of pro-inflammatory cytokines. Thus, it ensures safety while effectively depleting target cells.
(2) This platform is a universal platform capable of potently engulfing target cells expressing different TAAs.
(3) The Fc region of the antibody is engineered to enhance Fcy receptor function, achieving dual activation of myeloid cells and NK cells.
(4) This antibody has been engineered to enhance stability, antibody titer, and reduce structural heterogeneity. Therefore, it is optimized to improve CMC performance and developability.
In addition, unlike TCE, MCE kills target cells by recruiting myeloid cells, which are more prevalent in tumor tissues. Moreover, MCE exhibits a better safety profile in terms of cytokine release compared to TCE, showing great potential for expansion into the autoimmune field.
About LTZ TherapeuticsBiopharmaceuticals
LTZ Therapeutics was founded in 2022, byLi JinzeFounded by Dr. [Name], Dr. Martin Treder, and Dr. Jianhui Zhou. Currently, the company has research centers in Shenzhen, China, and Redwood City, California, USA, and a team based in Heidelberg, Germany.

EstablishmentTo date，LTZ TherapeuticsBiopharmaceuticalsTotalComplete FourRoundFinancing，RecruitmentFunds9000Ten ThousandUSD，RespectivelyFor：

  • Pre-ARound: In April 2022, LTZ Therapeutics announced the raising of US$17 millionPre-ARoundFinancing, led by K2 Venture Partners, with participation from Qiming Venture Partners and Tigermed.

  • Pre-A+Wheel：2023Year5Month，LTZ TherapeuticsBiopharmaceuticalsAnnouncementRaise over 10 million US dollarsPre-A+ RoundFinancing，Led by Qiming Venture Partners, Shunwei Capital,Lihé HóngxīnAnd K2Venture PartnersVenture capital participation.

  • ARoundFinancing：2024Year7Month，LTZ Therapeutics AnnouncesRaiseMore Than $20 Million in Series A Financing，ByNew investor Lapam Capital led the investment, with participation from GL Ventures. Additionally, they have obtainedExisting shareholder Qiming Venture Capital,K2 Venture Partners and Shunwei Capital's continued investment.

  • A+RoundFinancing：April 2025，LTZ TherapeuticsAnnounces Oversubscribed $40 Million Series A+ Financing，Led by new investor Wanshi Venture Capital, with participation from BlueRun Ventures, FiveSource Capital, Uniquex Capital, and the Follicular Lymphoma Innovation Research Institute. Existing shareholders Longpan Investment and Hillhouse Ventures continued to increase their investment.

Regarding this collaboration, Li Jinze, Founder and CEO of LTZ Therapeutics, stated: "We are very pleased to have reached a strategic cooperation agreement with GSK.This collaboration marks a crucial step in our mission to explore the potential of myeloid biology and provide new therapies for diseases with significant unmet medical needs."The collaboration with GSK in the field of oncology indications will enable us to accelerate the realization of this vision, bringing together the expertise of both parties and moving towards the common goal of improving patient outcomes."
Image

Image Source: PharmaTimes

$3.05 Billion! Johnson & Johnson Acquires Halda, Expanding into Innovative RIPTAC Therapy

2025-11-18

Image

$2.25 Billion! The Acquisition Battle Reignites as Lundbeck Outbids Alkermes to Secure Avadel

2025-11-17

Image

Where Did Pfizer's $10,000,000,000 Go?~

2025-11-16

Image

Copyright Statement/Disclaimer

This is a compiled article.

This article is for information exchange purposes only and does not provide any commercial, medical, or investment advice.

The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by Yaotimes, sourced from the WeChat public image library, taken from the company's official website/network, or used under the CC0 protocol. The copyright belongs to the respective owners, and Yaotimes makes every effort to credit the sources.

If you have any questions, please contact us.

Sincerely grateful!

DrugTimes Official Website: www.drugtimes.cn

Contact Information:

Phone: 13651980212

WeChat: 27674131

Email: contact@drugtimes.cn

图片
ImageClickView more exciting content!